HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model
Author Information
Author(s): Rai Myriam, Soragni Elisabetta, Jenssen Kai, Burnett Ryan, Herman David, Coppola Giovanni, Geschwind Daniel H., Gottesfeld Joel M., Pandolfo Massimo
Primary Institution: Laboratoire de Neurologie Expérimentale, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium
Hypothesis
Can HDAC inhibitors restore frataxin levels in a mouse model of Friedreich ataxia?
Conclusion
The study found that treatment with HDAC inhibitors can restore frataxin levels and gene expression profiles in a mouse model of Friedreich ataxia.
Supporting Evidence
- Treatment with compound 106 increased frataxin mRNA levels in KIKI mice.
- Histone modifications were altered in treated mice, indicating a more transcription-permissive state.
- Gene expression profiles in KIKI mice showed significant overlap with those in Friedreich ataxia patients.
Takeaway
Scientists tested a new drug on mice to see if it could help fix a problem in their cells that makes them sick, and it worked!
Methodology
Mice were treated with a histone deacetylase inhibitor and various tissues were analyzed for frataxin levels and gene expression.
Limitations
The study was conducted in a mouse model, which may not fully replicate human disease.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website